July Watch Lists

This month features a fairly diverse industry selection of Biotech, Pharmacological, Consumer Goods, Apparel, Infrastructure Products, Entertainment and IT Services.

It is also internationally diverse; from US, to China.

Here are the ones I am most interested in.

HRBN: designs, develops, manufactures, supplies, and services of various electric motors in China and internationally. This stock is showing good on balance volume, strength and money flow and I believe will soon break through 52 week highs. It is also in the markets current favorable China sector and stands to benefit as the world economy recovers and continues to grow.

FRPT: engages in the design, manufacture, testing, and delivery of blast and ballistic protected vehicles that support armed forces and security personnel in harm's way. They are also one of the main contenders and potential benficiaries of a soon to be awarded Gov’t contract for armored vehicles. As a result, this stock has been rising on good volume lately.

HGRD: provides proprietary objective healthcare provider ratings and advisory services in the United States. Its ratings address hospitals, nursing homes, and home health agencies. This stock has recently looked as it has/is breaking out above resistance and is ready for another run. I believe mostly due to all the recent talk and rhetoric regarding healthcare reform. This almost falls into the “hype” category and is worth watching.

NVEC: engages in the development and sale of devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. This falls into my “really cool” technology product that has the potential for hundreds of opportunities in lots of products and markets. It seems that the stock market has caught on to this potential as well and that makes this stock worth a closer look and watch.

ONTY: focuses on developing therapeutic products for the treatment of cancer. They recently have reported very favorable results regarding their product pipeline and have major backing and initiated Phase 3 testing with MERK. All very good news for any pharm stock.